SUMMARY

NCTTRAC and TDEM have partnered with MPP Infusion to create state-funded infusion sites in Irving and in Fort Worth. These sites will accept patient referrals from healthcare providers across the region to help administer COVID therapeutics quickly and safely with the ultimate goal of preventing patients from needing hospitalization.

ELIGIBILITY CRITERIA

Patients must meet at least one of the following criteria:

- ≥ 65 years of age
- BMI ≥ 35
- Has chronic kidney disease, diabetes, or immunosuppressive disease
- Currently receiving immunosuppressive treatment
- ≥ 55 years of age AND
  - Cardiovascular disease, hypertension, or chronic obstructive pulmonary disease/other chronic respiratory disease

Additionally, patients must meet ALL of the following criteria:

- COVID-positive & within 10 days of symptom onset
- Not asymptomatic and has mild to moderate illness
- Not hospitalized due to COVID-19
- Does not require oxygen therapy due to COVID-19 and has SpO₂ ≥ 94% on room air
- If pregnant, patient must be cleared with OB/GYN
- Has not received COVID-19 vaccine in last 90 days

CONTACTS

Referral Questions?
855-478-1528

Media Inquiries?
media@tdem.texas.gov

Key Points

- There are currently 2 sites – 1 in Fort Worth and 1 in Irving
- Patients must be referred by a physician, nurse practitioner, or PA – patients cannot refer themselves
- There is no “walk-in” availability; all treatments must be scheduled in advance
- Infusions utilize monoclonal antibody treatments including Bamlanivimab or the Regeneron Cocktail (Casirivimab & Imdevimab)
- This is a state-funded operation – there is no cost to the patient

Q: What documentation do I need to get the infusion?
A: You will need to provide a photo ID, such as a driver’s license, passport, work ID, parish ID, library card, or other form of photo ID.

Q: Who can refer a patient to these infusion centers?
A: Physicians, Nurse Practitioners, or Physician’s Assistants operating in Trauma Service Area E. There are no residency restrictions, nor are there limits on which physicians can refer or how many patients can be referred. Referrals can come from hospitals, Freestanding EDs, and physician offices.

Q: How is patient consent obtained?
A: MPP Infusion acquires HIPPA consents, consents to treat and completes an initial assessment. MPP Infusion requires a referral form and documentation from the visit outlining that the patient is at high risk and a prime candidate for therapy.

Q: What happens after a physician submits a patient referral?
A: MPP Infusion will contact the patient and the referring provider to conduct an initial assessment to ensure the disease has not progressed substantially and to schedule the infusion appointment.

Q: What is the daily capacity of the regional infusion centers?
A: The Irving and Fort Worth sites can each do 50 treatments in a 12-hour day.

Q: Where are these infusion centers getting their supply of treatments?
A: Initial supply of Bamlanivimab came directly from TDEM; initial supply of the Regeneron Cocktail have come from local hospitals. If your hospital is willing to share Bamlanivimab, Casiribimab, or Imdevimab with these regional infusion centers, please contact NCTTRAC_EMCC@ncttrac.org.